Protein vaccines utilize protein antigens, typically recombinant proteins produced in heterologous expression systems and based on pathogen sequences. Their administration aims to elicit a protective immune response. Genetic code expansion (GCE) is a cutting-edge technology that enables the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins using engineered orthogonal aaRS/tRNA pairs. As a leading provider of preclinical services, we leverage this powerful GCEngine platform for advanced vaccine design. By site-specifically integrating ncAAs into vaccine antigens, we enable the development of next-generation protein vaccines with the potential for enhanced immunogenicity, stability, and functionality, offering a novel approach to prophylactic and therapeutic vaccine development.
Overview of ncAA-Incorporated Protein Vaccines
Protein-based vaccines are defined by the use of specific antigenic proteins or particles (e.g., recombinant subunits, virus-like particles) as the immunogen. Representing a significant leap in molecular engineering, ncAA-incorporated protein vaccines involve the precise insertion of synthetic amino acids into antigenic proteins.
Unlike traditional methods that rely on random chemical conjugation, this approach allows the introduction of unique chemical handles (e.g., click chemistry groups, photo-crosslinkers, post-translational modification mimics) at predetermined sites, minimizing disruption to native protein folding and conformational epitopes. This precise control over antigen structure facilitates the design of vaccines that are not only chemically defined but also engineered for improved biochemical stability and targeted immune modulation.
Key Advantages of ncAA-Incorporated Protein Vaccines
- Precision Antigen Design: Site-specific ncAA insertion enables the generation of structurally defined antigens. This preserves conformational epitopes while allowing for modular, site-specific attachment of adjuvants (e.g., TLR ligands), carriers, or stability-enhancing polymers via bio-orthogonal chemistry.
- Potentiated Immunogenicity: The bio-orthogonal handles provided by ncAAs facilitate the precise conjugation of immunomodulatory molecules (e.g., adjuvants) or antigen-presentation enhancers. This enables optimized antigen delivery and processing, which may lead to more robust and tailored humoral and cellular immune responses.
- Optimized Stability and Pharmacokinetics: Incorporation of certain ncAAs can be leveraged to improve the thermal or proteolytic stability of vaccine antigens, potentially contributing to longer shelf-life and extended in vivo antigen exposure.
Our Services
Built upon years of expertise in orthogonal translation systems, our proprietary GCEngine platform provides an integrated solution from basic research to preclinical vaccine candidates. By focusing on the unique requirements of protein vaccines, specialized services are offered that include the optimization of incorporation sites to maximize both protein stability and immunological impact. Services encompass the identification and optimization of robust orthogonal aaRS/tRNA pairs via directed evolution and rational design, screening and validation of ncAA incorporation both in vitro and in stable mammalian cell lines, and the development and functional characterization of the engineered vaccine antigens.
Workflow of ncAA-Incorporated Protein Vaccine Development
- Antigen Design & Codon Strategy: Collaborative identification of optimal antigen targets and precise ncAA incorporation sites. Strategic selection of reassigned codons based on antigen sequence and the desired expression host.
- Orthogonal Pair Development & Engineering: Using high-throughput screening, directed evolution, and rational design, we develop or optimize highly efficient and specific orthogonal aaRS/tRNA pairs tailored to your selected ncAA and mammalian (or other) expression systems.
- Antigen Expression & Characterization: The engineered antigen is expressed and purified. We employ LC-MS/MS, HPLC, and SDS-PAGE to rigorously confirm site-specific incorporation, modification stoichiometry, protein integrity, and purity.
- Site-Specific Conjugation & Formulation: The bio-orthogonal functional group on the incorporated ncAA enables site-specific conjugation to adjuvants (e.g., TLR agonists), carrier proteins, or immunomodulators via click chemistry. We then develop and optimize the vaccine formulation for preclinical studies.
- Immunogenicity & Efficacy Assessment: Preclinical evaluation of vaccine candidates in relevant animal models. Analysis includes immunogenicity profiling (antibody titers, subtype, neutralization), cellular immune responses, and challenge studies to assess protective efficacy.
Types of ncAA-Incorporated Protein Vaccines
Our platform is versatile and can be applied to engineer a broad spectrum of advanced vaccine modalities. These include recombinant subunit antigens with site-specific modifications, virus-like particles displaying chemically defined, enhanced antigens, and rationally designed multi-epitope or mosaic antigens stabilized and optimized through ncAA incorporation.
Viral-Like Particles (VLPs)
Surface engineering through site-specific ncAA incorporation enables the controlled, covalent attachment of complex glycans, targeting ligands, or adjuvants. This precision allows for the fine-tuning of immunogenicity, thermal stability, and cell-specific targeting.
Precisely Engineered Subunit Vaccines
By replacing stochastic conjugation with bio-orthogonal chemistry, we can attach immunomodulators or stability-enhancing polymers to recombinant antigens at predefined sites. This ensures the production of uniform, high-potency immunogens.
Defined Conjugate Vaccines
We create well-defined conjugate vaccines by utilizing ncAAs as bio-orthogonal "handles" to link antigens (e.g., polysaccharides or haptens) to carrier proteins. This guarantees stoichiometry and site-specificity, ensuring batch-to-batch consistency.
Epitope Stabilization via ncAAs
For challenging targets, ncAAs are used to introduce stabilizing cross-links or other modifications. This "locks" antigens into immunologically relevant conformations (e.g., the prefusion state), focusing the immune response on conserved, vulnerable epitopes.
Customized Solutions for ncAA-Incorporated Protein Vaccine Development
Recognizing that every pathogen presents unique challenges, we collaborate closely with partners to design vaccine solutions that address specific disease mechanisms and immunological goals. For infectious diseases, it enables the engineering of stabilized antigens, such as prefusion-locked viral proteins, to focus immune responses on conserved epitopes. While infectious disease applications are actively explored, the platform provides a foundational toolset that may be adapted for future research in areas such as oncology and autoimmune disorders.
Contact Us
By offering a unique integration of deep GCE expertise with vaccine development know-how, we provide a distinct advantage in the quest for more effective and precisely engineered immunotherapies. Our GCEngine platform accelerates the transition from innovative concept to preclinical candidate, reducing the technical risks associated with advanced vaccine modalities. To explore how our ncAA-incorporated protein vaccine development services can accelerate your research and development goals, please contact us.
Reference
- Wang, Nanxi et al. "Construction of a live-attenuated HIV-1 vaccine through genetic code expansion." Angewandte Chemie 53.19 (2014): 4867-71.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
